{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-044598","form_type":"8-K","ticker":"LXEO","cik":"0001907108","company_name":"Lexeo Therapeutics, Inc.","filed_at":"2024-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:03:21.175096+00:00","generated_at":"2026-06-03T22:25:42.150110+00:00","sec_items":["8.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Lexeo Therapeutics receives FDA Fast Track designation for LX2006 gene therapy for FA cardiomyopathy","bullets":["FDA granted Fast Track designation for LX2006 (AAVrh.10hFXN gene therapy) for Friedreich's ataxia cardiomyopathy.","LX2006 aims to deliver functional frataxin gene to restore mitochondrial function in myocardial cells.","Phase 1/2 SUNRISE-FA trial ongoing to evaluate safety, tolerability, and preliminary efficacy in FA cardiomyopathy.","LX2006 previously received Rare Pediatric Disease and Orphan Drug designations; Fast Track may accelerate development.","FA cardiomyopathy is the leading cause of death among FA patients, with no approved treatments."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-044598","json":"https://secwatch.observer/filing/0000950170-24-044598.json","markdown":"https://secwatch.observer/filing/0000950170-24-044598.md","text":"https://secwatch.observer/filing/0000950170-24-044598.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024044598/0000950170-24-044598-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1907108/000095017024044598/lxeo-20240416.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T22:25:42.150110+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}